Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for PDAC

Ben George,Olga Kudryashova,Andrey Kravets,Samih Thalji,Subramaniam Malarkannan,Razelle Kurzrock,Ekatherina Chernyavskaya,Mariia Gusakova,Dmitry Kravchenko,Dmitry Tychinin,Egor Savin,Lolita Alekseeva,Anna Butusova,Aleksander Bagaev,Nara Shin,Jessica H Brown,Isha Sethi,Dandan Wang,Bradley Taylor,Thomas McFall,Mandana Kamgar,William A Hall,Beth Erickson,Kathleen K Christians,Douglas B Evans,Susan Tsai,Jessica H. Brown,William A. Hall,Kathleen K. Christians,Douglas B. Evans
DOI: https://doi.org/10.1053/j.gastro.2024.01.028
IF: 29.4
2024-01-01
Gastroenterology
Abstract:BACKGROUND: The complex tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) has hindered the development of reliable predictive biomarkers for targeted therapy and immunomodulatory strategies. A comprehensive characterization of the TME is necessary to advance precision therapeutics in PDAC.METHODS: A transcriptomic profiling platform for TME classification based on functional gene signatures was applied to 14 publicly available PDAC datasets (n = 1657) and validated in a clinically annotated independent cohort of patients with PDAC (n = 79). Four distinct subtypes were identified using unsupervised clustering and assessed to evaluate predictive and prognostic utility.RESULTS: TME classification using transcriptomic profiling identified 4 biologically distinct subtypes based on their TME immune composition: immune enriched (IE); immune enriched, fibrotic (IE/F); fibrotic (F); and immune depleted (D). The IE and IE/F subtypes demonstrated a more favorable prognosis and potential for response to immunotherapy compared with the F and D subtypes. Most lung metastases and liver metastases were subtypes IE and D, respectively, indicating the role of clonal phenotype and immune milieu in developing personalized therapeutic strategies. In addition, distinct TMEs with potential therapeutic implications were identified in treatment-naive primary tumors compared with tumors that underwent neoadjuvant therapy.CONCLUSIONS: This novel approach defines a distinct subgroup of patients with PDAC who that may benefit from immunotherapeutic strategies based on their TME subtype and provides a framework to select patients for prospective clinical trials investigating precision immunotherapy in PDAC. Further, the predictive utility and real-world clinical applicability espoused by this transcriptomic-based TME classification approach will accelerate the advancement of precision medicine in PDAC.
gastroenterology & hepatology
What problem does this paper attempt to address?